Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.

ABSTRACT: Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.

SUBMITTER: Marabelle A 

PROVIDER: S-EPMC3817012 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature